Cytodyn Inc (CYDY)

[JPG77]

WRONG. The 350mg NASH results were excitingly good and MET THEIR END POINTS! BPs are salivating over the results - that's common knowledge and negative spin from the shorts can't revise history. Regardless, the 700mg results (twice the dosage) should be amazing!

"The NASH trial achieved the primary endpoint of proton density fat fraction (PDFF) and the secondary endpoint of cT1. PDFF is an MRI-derived biomarker for fatty deposition, while cT1 is an iron-corrected T1 mapping indicator of fibrosis and liver inflammation. Both endpoints were used to assess the NASH risk.

Participants were given leronlimab weekly during the two-part NASH trial. Part I observed a weekly dose of 700 mg versus a placebo in double-blind and randomized setting. Part II looked into a weekly dose of 350 mg versus placebo in an open label study. Topline results are expected to be announced soon. The researchers found a statistically significant improvement in the 350 mg dose group for both the primary and secondary endpoints. "

LL NASH 350 mg was mediocre and is not competitive with the leading NASH competitors